On the stock market since 2021, it operates in the world of health and science. It has 122 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 93% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 37% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 39% a year on average.
Sales run at $15.8M a year. A small number, but proof the product has real buyers.
The average analyst price target is $6.00 — 21% above today’s price.
A loss of $13.7M against $15.8M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 18 sells against just 5 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, GRVI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GRVI is a high-risk stock — not yet profitable, and its future rides on its product catching on.